The company has seen its value grow by a whopping 431% since its Initial Public Offering. As a result, CureVac was able to get up to $231 million in initial funding, which is expected to go towards research and development.
For almost two decades, he relied on this bank for financing during a time when other banks refused to lend him money. Now, this relationship is being investigated by the New York attorney General.